Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium

• Status: Recruiting
• Trial end date: 2021-12-15
• Target enrollment: 0
• Participant gender: All

Summary

The administration of acetylcholinesterase inhibiting agents (such as neostigmine) has been used to reverse the muscle paralysis induced by non-depolarizing neuromuscular blocking agents. It is not well known whether there is a difference between the time required for complete reversion of moderate neuromuscular blockade (NMB) after the administration of neostigmine in usual doses when compared to the reversion of superficial NMB with the use of a reduced dose of the same agent (excessive doses of neostigmine administered during superficial blocks may cause paradoxical muscle weakness). The aim of the present study will be to compare, by means of a prospective, randomized, controlled and double-blind clinical trial, the times necessary for the reversion of moderate block with neostigmine 60 mcg / kg or for superficial block to reach values of T4 / T1> 0.9 using neostigmine 30 mcg / kg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pontificia Universidade Catolica de Sao Paulo
• Treatments: Iodine

Criteria

Inclusion Criteria:

• Patients aged between 18 and 65 years

• Undergoing general anesthesia for nose and ear surgery

• Physical status according to the American Society of Anesthesiologists I and II

Exclusion Criteria:

• Refusal to participate in the study

• Presence of kidney, liver or neuromuscular disease

• Contraindication to the use of any of the drugs used in the study

• Body mass index (BMI) ≥ 30